United BioPharma Inc (6471):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:United BioPharma Inc (6471) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9365
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:21
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:台湾
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
United BioPharma Inc (United BioPharma) is a pharmaceutical company. The company develops, manufactures, and markets monoclonal antibody (mAb) products and biosimilar antibodies. Its molecules product pipeline includes UB-421, a monoclonal antibody for AIDS treatment; and UB-621, an anti-herpes simplex virus (HSV) monoclonal antibody. United BioPharma offers UB-221, an anti-allergic monoclonal antibody; and UB-721, a biosimilar antibody for anti-autoimmune disease. The company also provides UB-923, UB-925, UB-923, UB-921 and UB-922 for malignant tumour. It has operations throughout the US and China. United BioPharma is headquartered in Hukou, Taiwan.

United BioPharma Inc (6471) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
United BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
United BioPharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
United BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
United BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
United BioPharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
United BioPharma Inc, Pharmaceuticals & Healthcare, Deal Details 10
Licensing Agreements 10
United BioPharma Enters into Licensing Agreement with Academia Sinica for Cancer 10
United BioPharma Enters into Licensing Agreement with Academia Sinica 11
Equity Offering 12
United BioPharma to Raise USD26.8 Million in Rights Offering of Shares 12
United BioPharma to Raise USD1.8 Million in Rights Offering of Shares 13
United BioPharma Raises USD15.6 Million in Public Offering of Shares 14
United BioPharma Raises USD27.8 Million in the Private Placement of Shares 15
United BioPharma Inc – Key Competitors 16
United BioPharma Inc – Key Employees 17
United BioPharma Inc – Locations And Subsidiaries 18
Head Office 18
Other Locations & Subsidiaries 18
Recent Developments 19
Strategy And Business Planning 19
Apr 04, 2017: United BioPharma holds an inauguration ceremony marking the opening of its new manufacturing plant 19
Other Significant Developments 20
Mar 05, 2018: UBP Construction Plan to start on new facility for biopharmaceutical manufacturing in China 20
Appendix 21
Methodology 21
About GlobalData 21
Contact Us 21
Disclaimer 21

List of Tables
United BioPharma Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
United BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
United BioPharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
United BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
United BioPharma Inc, Deals By Therapy Area, 2012 to YTD 2018 8
United BioPharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
United BioPharma Enters into Licensing Agreement with Academia Sinica for Cancer 10
United BioPharma Enters into Licensing Agreement with Academia Sinica 11
United BioPharma to Raise USD26.8 Million in Rights Offering of Shares 12
United BioPharma to Raise USD1.8 Million in Rights Offering of Shares 13
United BioPharma Raises USD15.6 Million in Public Offering of Shares 14
United BioPharma Raises USD27.8 Million in the Private Placement of Shares 15
United BioPharma Inc, Key Competitors 16
United BioPharma Inc, Key Employees 17
United BioPharma Inc, Other Locations 18

List of Figures
United BioPharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
United BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
United BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
United BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
United BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
United BioPharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
United BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
United BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[United BioPharma Inc (6471):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Emcure Pharmaceuticals Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Emcure Pharmaceuticals Ltd (Emcure) develops, manufactures and markets a range of pharmaceutical products worldwide. The company specializes in the development and manufacture of differentiated pharmaceutical products. It also manufactures active pharmaceutical ingredients (APIs) primarily f …
  • SINTX Technologies Inc (SINT)
    SINTX Technologies Inc (SINT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company
  • Genera Biosystems Ltd (GBI):製品パイプライン分析
    Summary Genera Biosystems Ltd (GBL) is a developer and commercializer of multiplexed molecular diagnostic testing products. The company offers RTIplex and PapType molecular diagnostic test. Its RTIplex is a multiplexed and automated PCR based test for detection of viral and bacterial respiratory pat …
  • Seafarms Group Limited (SFG):企業の財務・戦略的SWOT分析
    Seafarms Group Limited (SFG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Nuvelution Pharma Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Nuvelution Pharma Inc (Nuvelution Pharma) is a developer of late-stage clinical assets. The company offers research and development risk-sharing approach to pharmaceutical and biotechnology companies. It facilitates advancement of late-stage clinical assets where research and development bud …
  • WH Group Limited (288):企業の財務・戦略的SWOT分析
    WH Group Limited (288) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Sichuan Chuantou Energy Company Ltd (600674):電力:M&Aディール及び事業提携情報
    Summary Sichuan Chuantou Energy Company Ltd (Sichuan Investment Energy), a subsidiary of Sichuan Investment Group Co Ltd is an investment holding company. The company’s business activities include operation of hydropower stations, thermal power plant and power generation plants. It develops, constru …
  • RWE AG (RWE):石油・ガス:M&Aディール及び事業提携情報
    Summary RWE AG (RWE) is an energy company. It has presence in the energy value chain, from lignite production and electricity generation, to energy trading and operation of distribution networks, and supply of electricity, gas and energy solutions. The company produces electricity using conventional …
  • DPL Inc. (DPL):電力:M&Aディール及び事業提携情報
    Summary DPL Inc. (DPL) a subsidiary of AES Corporation is a diversified energy and utility company. It is engaged in the generation, transmission and distribution of electricity in West Central Ohio. The company provides its services to residential, commercial, and industrial and government customer …
  • The Ensign Group Inc (ENSG):企業の財務・戦略的SWOT分析
    The Ensign Group Inc (ENSG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Kurganmashzavod JSC:企業の戦略的SWOT分析
    Kurganmashzavod JSC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • BDO Unibank Inc:企業の戦略・SWOT・財務情報
    BDO Unibank Inc - Strategy, SWOT and Corporate Finance Report Summary BDO Unibank Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Bimini Capital Management, Inc.:企業の戦略・SWOT・財務情報
    Bimini Capital Management, Inc. - Strategy, SWOT and Corporate Finance Report Summary Bimini Capital Management, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Siemens Medical Solutions USA Inc:企業のM&A・事業提携・投資動向
    Siemens Medical Solutions USA Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Siemens Medical Solutions USA Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mer …
  • Laboratoires Pierre Fabre SA:製薬・医療:M&Aディール及び事業提携情報
    Summary Laboratoires Pierre Fabre SA (Pierre Fabre), a subsidiary of Pierre Fabre Foundation develops products and solutions ranging from health to beauty. Its product portfolio comprises wide range of complementary products, from prescribed drugs to dermo-cosmetics, including over-the-counter drugs …
  • SPIE Nucleaire:企業の戦略的SWOT分析
    SPIE Nucleaire - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • ShanPar Industries Pvt. Ltd. :企業の戦略・SWOT・財務情報
    ShanPar Industries Pvt. Ltd. - Strategy, SWOT and Corporate Finance Report Summary ShanPar Industries Pvt. Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • K-Electric Ltd (KEL):企業の財務・戦略的SWOT分析
    K-Electric Ltd (KEL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • SPX Flow Inc (FLOW):企業の財務・戦略的SWOT分析
    SPX Flow Inc (FLOW) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Flexion Therapeutics Inc (FLXN)-製薬・医療分野:企業M&A・提携分析
    Summary Flexion Therapeutics Inc (Flexion) is a pharmaceutical company that develops and commercializes pain therapies. The company's products comprise FX006, FX007, and FX005. Its FX005 is a p38 mitogen-activated protein, kinase inhibitor that contains both analgesic and anti-inflammatory propertie …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆